Clinical Supply Planning Articles

1. Tariffs Threaten Clinical Trial Supply Chains: Preparing For Volatility 2/10/2026

   Tariffs and FDA staffing gaps are quietly reshaping clinical trial supply chains. From comparators to customs delays, these forces are creating real risk for timelines, budgets, and patients.

2. How Clinical Supply Teams Pull Better Demand Signals 2/6/2026

   Clinical supply teams reduce risk by using site-level enrollment data, screen failure rates, and amendment impacts to guide material commitments and plan for uncertainty.

3. Why Clinical Supply Risk Starts With Demand Signals 2/5/2026

   Clinical supply risk often begins long before manufacturing or distribution. Flawed demand signals and enrollment forecasts can quietly create shortages, delays, and costly material waste.

4. Clinical Supply Planning In A More Volatile And Regionalized World 2/4/2026

   Global shifts are rewriting the rules of clinical supply. Rising costs, regional regulations, and material scarcity mean planners must rethink strategies or risk costly disruptions.

5. Global Clinical Supply — Confronting Persistent Challenges With Strategic Action 1/21/2026

   From regulatory fragmentation to cold chain risks, discover how strategic action, data visibility, and resilient design keep clinical trials on track.

6. Clinical Supply Is Not A Fix-It Function. It's A Planning Function. 1/9/2026

   Treating clinical supply as a late-stage fix creates delays, shortages, and cost overruns. Early planning—across DP availability, forecasting, QP release, labels, and IXRS—keeps trials on timeline and out of crisis.

7. Sales & Operations Planning for Small Teams: Aligning Clinical Supply 1/6/2026

   Small clinical teams don’t fail at S&OP from missing systems—they fail from unclear demand and decisions. Alignment comes from discipline, shared visibility, and acting on reality before timelines slip.

8. The Trends Shaping Clinical Trial Supply 12/22/2025

   Decentralized trials and biotech product needs are changing how investigational products reach patients. New market research reveals trends.

9. Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development 10/21/2025

   Discover how partnerships — especially with capable CROs — as well as resilient supply chains, digital enablement, regulatory foresight, and specialized talent impact the success of targeted protein degradation therapies.

10. What Can The Tech Sector's 'Minimally Viable' Concept Teach Biopharma? 10/9/2025

    Deciding what is good enough to get started can support the mindset of building something without sacrificing quality, functionality, or safety.